You are here

Article Text

Article menu
Letter
Bilateral acute anterior uveitis after alendronate
  1. A R Malik,
  2. S H Campbell,
  3. N M G Toma
  1. Moorfields Eye Hospital, City Road, London EC1V 2PD, UK
  1. Correspondence to: Dr Malik; amber_r_malik{at}hotmail.com

https://doi.org/10.1136/bjo.86.12.1443

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Biphosphonates are increasingly being used for the prevention and treatment of osteoporosis in women where hormone replacement therapy is contraindicated.1,2 Alendronate (Fosamax) is a potent aminobiphosphonate that reduces bone resorption and increases bone mass and therefore reduces the incidence of fractures in postmenopausal women with osteoporosis.2 The most common adverse effects are upper gastrointestinal, including dysphagia, heartburn, oesophagitis, and oesophageal strictures. We report a case of bilateral acute anterior uveitis following the use of alendronate (once weekly 70 mg tablet). This is the first reported case of bilateral acute anterior uveitis associated with alendronate.

    Case report

    A 57 year old woman had been taking oral alendronate 10 mg daily for a year without experiencing any eye problems. To simplify the regimen her general practitioner proposed a single weekly dose …

    View Full Text